NaifaL.BusaidyMD

Endocrinology • Houston, TX

Diabetes, Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine, Thyroid

Physician

Join to view full profile

Dr. Busaidy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Busaidy's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

Baylor College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 2001 - 2004
Baylor College of MedicineResidency, Internal Medicine, 1998 - 2001
Baylor College of MedicineClass of 1997

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2022 - 2026
GA State Medical License 2022 - 2026
TN State Medical License 2022 - 2026
AL State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 2004 - 2025
WA State Medical License 2022 - 2025
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Join now to see all

Awards, Honors, & Recognition

Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

Continuous Glucose Monitoring in Critically Ill Start of enrollment: 2008 Jun 01
Terminated
Not Applicable
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Start of enrollment: 2012 Nov 07
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.
Sarah Hamidi, Sireesha Yedururi, Mimi I Hu, Naifa L Busaidy, Steven I Sherman
Thyroid. 2024-12-04
[18F]-Fluorodeoxyglucose Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma Following BRAF-Targeted Therapy.
Samir A Dagher, Kim O Learned, Richard Dagher, Jennifer Rui Wang, Xiao Zhao
AJNR. American Journal of Neuroradiology. 2024-11-21
Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer.
Julianna K Bronk, Alexander Augustyn, Abdallah S R Mohamed, C David Fuller, Adam S Garden
Radiotherapy and Oncology. 2024-11-01

Journal Articles

Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine
Thinh Vu, Naifa L Busaidy, Maria E Cabanillas, Steven G Waguespack, Steven I Sherman, Mark Zafereo, The Journal of Clinical Endocrinology and Metabolism
Selective RET Kinase Inhibition for Patients with RET-Altered Cancers
L J Wirth, N L Busaidy, M E Cabanillas, Annals of Oncology

Lectures

Safe and Effective Dosing of Basal-Bolus Insulin in Patients Receiving High-Dose Steroids for Hyper-CVAD Chemotherapy
Houston, TX - 6/14/2014

Press Mentions

VIDEO: Thyroid ‘Year in Review’ Covers Clinical Studies with ImpactNovember 1st, 2019
$New Treatments, New Outcomes for Refractory Thyroid Cancer$
New Treatments, New Outcomes for Refractory Thyroid CancerJuly 10th, 2019
The Future of Cancer Diagnosis and Treatment: Liquid Biopsies Can Reveal Cancer and MoreNovember 13th, 2017